Despite reports of neurological manifestations in both children and adults with COVID-19, the neurological manifestations of children with recently described severe post‐infectious immune‐mediated disorder pediatric inflammatory multisystem syndrome temporally associated with the SARS-CoV-2 (PIMS-TS) are not well known. To fill this gap, researchers assessed data on patients with a median age of 10.1 presenting to a hospital between March 1, 2020 and June 21, 2020 who fulfilled PIMS-TS criteria. Among participants, 51.1% reported new-onset neurological symptoms, including headache, encephalopathy, dysarthria/dysphonia, hallucinations, ataxia, peripheral nerve involvement, and seizures. Splenium signal changes were observed in 28.6% of patients on brain MRI, mild excess of slow activity in 100% who underwent an EEG, and mild myopathic and neuropathic changes in 80% who underwent nerve conduction studies and electromyography. Patients with neurological involvement, when compared with those without it, had higher peak inflammatory markers, were more likely to be ventilated, and were more likely to require inotropic support in the pediatric ICU.
